COMMUNIQUÉS West-GlobeNewswire

Canadians trust their dentist as much as their family doctor, and 8 in 10 support the Canadian Dental Care Plan: 123Dentist national survey
29/10/2026
As the Auditor General releases their report, 6 in 10 Canadian Dental Care Plan enrollees say the program helped them receive care they otherwise could not have. TORONTO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Canadians [...]
Les Canadien·ne·s font autant confiance à leur dentiste qu’à leur médecin de famille, et 8 sur 10 appuient le Régime canadien de soins dentaires : sondage national de 123Dentiste
29/10/2026
Au moment où la vérificatrice générale publie son rapport, 6 personnes inscrites sur 10 affirment que le Régime canadien de soins dentaires leur a donné accès à des soins autrement hors de portée TORONTO, 29 oct. 2026 ( [...]
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
29/10/2026
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families STOUGHTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE [...]
Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET
29/10/2026
Company to report third quarter 2026 financial results on November 5 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range [...]
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
29/10/2026
Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include [...]
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
29/10/2026
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment [...]
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
29/10/2026
U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis Company expands pipeline through research [...]
Oak Hill Bio to Present at Upcoming Investor Conferences
29/10/2026
CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- OHB Pediatrics Ltd d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced that the company will participate in the following investor [...]
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
29/10/2026
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company [...]
Immutep Quarterly Activities Report Q1 FY27
29/10/2026
Media Release Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway [...]
Breckenridge Distillery and University of Denver Athletics Release Limited-Edition Whiskey Celebrating Record 11th NCAA Men’s Hockey Championship
29/10/2026
$100 from every bottle sold will benefit Denver men’s ice hockey scholarships DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , an award-winning craft distillery and subsidiary of Tilray Brands, Inc. ( [...]
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
29/10/2026
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the [...]
MediWound to Report Third Quarter 2026 Financial Results
29/10/2026
MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a [...]
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
29/10/2026
Peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care. SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the [...]
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
29/10/2026
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus patients [...]
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
29/10/2026
BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Verano Announces Strong Third Quarter 2026 Financial Results Highlighted by $212 Million in Revenue and Year-Over-Year Organic Growth
29/10/2026
Company generates revenue increase of $10 million, or 5%, and highest level of cash flow from operations in four years CHICAGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“ [...]
Ligand Reports Third Quarter 2026 Financial Results
29/10/2026
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8: [...]
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
29/10/2026
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage [...]

Pages